Fluvastatin

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1994 • 8,631 citations

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

1995 • 7,378 citations

Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia

1987 • 3,889 citations

The Lipid Research Clinics Coronary Primary Prevention Trial Results

1984 • 2,673 citations

Prescribing Personalized Nutrition for Cardiovascular Health: Are We Ready?

2014 • 1,880 citations

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).

1994 • 809 citations

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

1984 • 631 citations

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia

1991 • 489 citations

Efficacy and long-term adverse effect pattern of lovastatin

1988 • 338 citations

HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits.

1993 • 229 citations

Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase

1993 • 215 citations

Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme a reductase

1994 • 191 citations

Clinical Pharmacokinetics and Practical Applications of Simvastatin

1993 • 182 citations

Pharmacokinetics of Fluvastatin After Single and Multiple Doses in Normal Volunteers

1992 • 170 citations

Change in Cholesterol Awareness and Action

1991 • 141 citations

Plasma Concentration Profiles of Simvastatin 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitory Activity in Kidney Transplant Recipients with and without Ciclosporin

1993 • 138 citations

A review of clinical trials comparing HMG-CoA reductase inhibitors.

1994 • 136 citations

Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association

1993 • 123 citations

Mechanism of Action and Biological Profile of HMG CoA Reductase Inhibitors

1988 • 114 citations

Long-term safety and efficacy profile of simvastatin

1991 • 113 citations

Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients.

1993 • 113 citations

Simvastatin

1995 • 108 citations

Fluvastatin with and without niacin for hypercholesterolemia

1994 • 93 citations

Pharmacokinetics of Fluvastatin and Specific Drug Interactions

1993 • 82 citations

Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation

1994 • 82 citations

Biotransformation of fluvastatin sodium in humans.

1993 • 81 citations

Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.

1993 • 81 citations

Simvastatin: The clinical profile

1989 • 80 citations

Expanded clinical evaluation of lovastatin (EXCEL) study results II. Assessment of the human lens after 48 weeks of treatment with lovastatin

1991 • 79 citations

Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes

1991 • 76 citations

Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors.

1990 • 74 citations

A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin.

1993 • 72 citations

Low-dose lovastatin safely lowers cholesterol after cardiac transplantation.

1990 • 69 citations

Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin

1994 • 67 citations

Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans

1991 • 61 citations

Comparison of Fluvastatin and Lovastatin Blood-Brain Barrier Transfer Using In Vitro and In Vivo Methods

1993 • 59 citations

Preventive effect of MK-733 (simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits.

1989 • 58 citations

Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase

1990 • 56 citations

Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias

1992 • 54 citations

Lovastatin. Warfarin interaction

1990 • 54 citations

Low-Dose Combined Therapy with Fluvastatin and Cholestyramine in Hyperlipidemic Patients

1994 • 53 citations

Updated clinical safety experience with fluvastatin

1994 • 53 citations

Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.

1994 • 53 citations

Fluvastatin long-term extension trial (FLUENT): Summary of efficacy and safety

1994 • 52 citations

Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: Comparative analysis with a fluvastatin-cholestyramine combination

1994 • 47 citations

Lack of interaction between fluvastatin andoral nypoylycemie agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus

1995 • 38 citations

Binding of Fluvastatin to Blood Cells and Plasma Proteins

1993 • 38 citations

Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia

1995 • 36 citations

Clinical implications of the biopharmaceutical properties of fluvastatin

1994 • 36 citations

Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia

1994 • 34 citations

Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.

1994 • 32 citations

A Randomized Multicenter Trial Comparing the Efficacy of Simvastatin and Fluvastatin

1996 • 30 citations

Prevention of restenosis after coronary balloon angioplasty: Rationale and design of the fluvastatin angioplasty restenosis (FLARE) trial

1994 • 29 citations

Double-Blind Comparison of the Efficacy and Tolerability of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolaemia

1995 • 29 citations

Combination therapy with fluvastatin and niacin in hypercholesterolemia: A preliminary report on safety

1994 • 29 citations

Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells

1993 • 26 citations

Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coeezyme a reduefase inhibitor

1995 • 26 citations

Fluvastatin administration of bedtime versus with the evening meal: A multicenter comparison of bioavailability, safety, and efficacy

1994 • 26 citations

Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine

1994 • 24 citations

Efficacy of a low dose‐range of fluvastatin (XU 62‐320) in the treatment of primary hypercholesterolaemia. A dose‐response study in 431 patients. The French‐Dutch Fluvastatin Study Group.

1994 • 24 citations

Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin

1994 • 23 citations

Simvastatin but not pravastatin has a direct inhibitory effect on rat and human myocyte proliferation

1992 • 23 citations

The interaction of fluvastatin and cyclosporin A in renal transplant patients.

1995 • 22 citations

Treatment of primary hypercholesterolemia: Fluvastatin versus bezafibrate

1994 • 21 citations

Efficacy and Safety of Fluvastatin in Hypertensive Patients: An Analysis of a Clinical Trial Database

1993 • 21 citations

Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolaemia

1993 • 21 citations

Long-term treatment of hypercholesterolemia with fluvastatin: A 52-week multicenter safety and efficacy study

1994 • 21 citations

Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia

1994 • 21 citations

The effect of simvastatin treatment on the low-density lipoprotein subfraction profile and composition in familial hypercholesterolaemia.

1993 • 21 citations

Simvastatin

1992 • 21 citations

Fluvastatin in familial hypercholesterolemia: A cohort analysis of the response to combination treatment

1994 • 20 citations

Long-term experience with pravastatin in clinical research trials.

1993 • 20 citations

Epidemiology of Hypercholesterolemia and European Management Guidelines

1990 • 20 citations

Baseline characteristics of subjects in the lipoprotein and coronary atherosclerosis study (LCAS) with fluvastatin

1994 • 18 citations

Absorption and disposition of fluvastatin, an inhibitor of HMG‐CoA reductase, in the rabbit

1992 • 17 citations

Fluvastatin and niacin in hypercholesterolemia: A preliminary report on gender differences in efficacy

1994 • 17 citations

Effects of simvastatin on serum lipids and atherosclerosis in WHHL rabbits.

1991 • 16 citations

Effects of Alcohol and Fluvastatin on Lipid Metabolism and Hepatic Function

1995 • 16 citations

Fluvastatin in primary hypercholesterolemia: Efficacy and safety in patients at high risk

1994 • 14 citations

Fluvastatin reduces levels of plasma apo B-containing particles and increases those of LpA-I

1994 • 14 citations

Efficacy and Safety of Fluvastatin in Women with Primary Hypercholesterolaemia

1994 • 14 citations

Safety and Tolerability of Fluvastatin With Concomitant Use of Antihypertensive Agents: An Analysis of a Clinical Trial Database

1993 • 14 citations

Long-term efficacy with fluvastatinas monotherapy and combined with cholestyramine (A 156-week multicenter study)

1995 • 13 citations

Efficacy and Safety of Fluvastatin, a New HMG CoA Reductase Inhibitor, in Elderly Hypercholesterolaemic Women

1994 • 12 citations

Cost-Effectiveness of Drug Therapy for Hypercholesterolaemia

1992 • 12 citations

Effect of fluvastatin sodium on secretion of very low density lipoprotein and serum cholesterol levels. In vivo study using low density lipoprotein receptor deficient watanabe heritable hyperlipidemic rabbits.

1994 • 11 citations

Gender-Related Response to Fluvastatin in Patients with Heterozygous Familial Hypercholesterolaemia

1994 • 9 citations

Fluvastatin, a New Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase, Suppresses very Low-Density Lipoprotein Secretion in Puromycin Aminonucleoside-Nephrotic Rats

1994 • 8 citations

Fluvastatin in severe hypercholesterolemia:Analysis of a clinical trial database

1995 • 7 citations

Health and economic issues in theprevention of coronary artery disease

1995 • 4 citations

Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). European Fluvastatin Study Group.

1994 • 4 citations